

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN THE Application of: Arthur A. Vandembark

Application No.: 09/853,830

Filed: May 10, 2001

For: METHODS OF IDENTIFYING AND
MONITORING DISEASE-ASSOCIATED
T CELLS

Examiner: Carla J. Myers


Date: November 19, 2002

Art Unit: 1634

RECEIVED
DEC 02 2002
TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on November 19, 2002 as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.


 Susan Alpert Siegel, Ph.D.
 Agent for Applicant

TRANSMITTAL LETTER

COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

Enclosed is an Amendment in Response to Paper No. 12 for the above application. The fee has been calculated as shown below.

CLAIMS AS AMENDED					
For	No. after amendment	No. paid for previously	Present Extra	Rate	Fee
Total Claims	32	- 32*	= 0	\$9.00	\$ 0.00
Indep. Claims	1	- 3**	= 0	\$42.00	\$ 0.00
Mult. Dep. Claims Fee (if not previously paid)					\$140.00
One-month Extension of Time					\$55.00
Two-month Extension of Time					\$200.00
Three-month Extension of Time					\$460.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$55.00

* greater of twenty or number for which fee has been paid.

** greater of three or number for which fee has been paid.

Applicant petitions for an extension of time for the number of months indicated above. If an additional extension of time is required please consider this a petition therefor.

A check in the amount of \$55.00 is attached.

- Please charge any additional fees that may be required in connection with filing this amendment and any extension of time, or credit any overpayment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.
- Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP


By



Susan Alpert Siegel, Ph.D.
Registration No. 43,121

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

cc: Docketing



SAS:sas 11/19/02 153264

Attorney Reference Number 899-63207
Application Number 09/853,830

RECEIVED

DEC 02 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Vandenbark

Application No. 09/853,830

Filed: May 10, 2001

For: METHODS OF IDENTIFYING AND
MONITORING DISEASE-ASSOCIATED T
CELLS

Examiner: Carla J. Myers


Date: November 19, 2002

Art Unit: 1634

TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on November 19, 2002 as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.


Susan Alpert Siegel, Ph.D.
Agent for Applicant

#B
CD
12/11/02

COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

AMENDMENT IN RESPONSE TO PAPER NO. 12

This amendment is submitted in response to the Office action, dated September 27, 2002, for which a one-month period for reply was set, making a response due on or before October 27, 2002. Applicants petition herein for a one month extension of time, and submit the required fee herewith, making this response due on or before November 27, 2002. Please enter the following remarks.

REMARKS

Restriction Requirement

In response to the restriction requirement, Applicants elect herein Group I, with traverse. Applicants submit that it would not be an undue burden upon the Examiner to search the subject matter of Groups I and II together, as both are directed to methods identifying a TCR variable region expressed by target cells. Clearly, claim 1 is generic to assaying for TCR variable region polypeptides and TCR variable region polypeptides. Methods for assaying for the presence of a polypeptide or a polynucleotide are well known in the art. Thus it would not be an undue burden

to search Group I and Group II together. Reconsideration and withdrawal of the restriction requirement is respectfully requested.

In addition, it would not be an undue burden on the Examiner to search the subject matter of Group I together with the subject matter of Group III. Group I is directed to methods of assaying for TCR V gene expression by assaying for TCR V nucleic acids. These methods include the use of TCR V gene specific probes and primers. Group III includes kits including TCR V gene probes and primers for the detection of TCR V genes. Clearly, it would not be an undue burden on the Examiner to search the methods of detecting TCR V nucleic acids with kits including nucleic acids for the detection of TCR V nucleic acids. Reconsideration of the restriction requirement is respectfully requested.


Conclusion

If any minor matters remain to be addressed prior to examination, the Examiner is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By


Susan Alpert Siegel, Ph.D.
Registration No. 43,121

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446